Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 69, Issue 6, 2010, Pages 987-994

  Knevel, Rachel ^a   Schoels, M ^b   Huizinga, T W J ^a   Aletaha, D ^c   Burmester, G R ^d   Combe, B ^e   Landewe R B ^f   Smolen, J S ^c   Sokka, T ^g   Van Der Heijde, D M F M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HIETZING HOSPITAL   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d HUMBOLDT UNIVERSITY   (Germany)

^e UNIV MONTPELLIER   (France)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE;

ADD ON THERAPY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COCHRANE LIBRARY; COMPARATIVE STUDY; EUROPE; EXPERT SYSTEM; HUMAN; MEDLINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 77953718691     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.126748     Document Type: Article

References (33)

1. Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis 2004;63:627-33.
2. Combe B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Clin Rheumatol 2007;21:27-42.
3. Klarenbeek NB, Allaart CF, Kerstens PJ, et al. The BeSt story: on strategy trials in rheumatoid arthritis. Curr Opin Rheumatol 2009;21:291-8.
4. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations 2010 for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-975.
5. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
6. Verstappen SM, Jacobs JW, Bijlsma JW. The Utrecht experience with different treatment strategies in early rheumatoid arthritis. Clin Exp Rheumatol 2003;21(5 Suppl 31):S165-8.
7. Fransen J, Moens HB, Speyer I, et al. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 2005;64:1294-8.
8. Symmons D, Tricker K, Roberts C, et al. The British Rheumatoid Outcome Study Group (BROSG). randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. Health Technol Assess 2005;9:iii-iv, ix-x, 1-78.
9. Symmons D, Tricker K, Harrison M, et al. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs - results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial. Rheumatology 2006;45:558-65.
10. van Hulst LTC, Creemers MCW, Fransen J, et al. Monitoring disease activity in RA: is strict treatment protocol really needed [abstract]? Ann Rheum Dis 2008;67(Suppl II):158.
11. Allaart CF, Breedveld FC, Dijkmans BA. Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study. J Rheumatol Suppl 2007;80:25-33. (Pubitemid 350076865)
12. Stenger AA, Van Leeuwen MA, Houtman PM, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998;37:1157-63.
13. van der Woude D, Visser K, Brand R, et al. Improved Outcomes of Drug-Free Remission with DAS-Steered Therapy Compared to Conventional Therapy for Rheumatoid Arthritis. ACR/ARHP [abstract] Annual Scientific Meeting 2008.
14. van Tuyl LH, Lems WF, Voskuyl AE, et al. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 2008;67:1574-7.
15. Edmonds J, Lassere M, Sharp J, et al. Objectives Study RA (OSRA): A RCT Defining the Best Clinical Target Control in RA. ACR [abstract] 2007.
16. Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
17. Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004;50:2072-81.
18. Rantalaiho VM, Korpela M, Kautiainen H, et al. Patients with early rheumatoid arthritis initially treated with a combination of DMARDs have higher remission rate over time than those randomized to monotherapy. Preliminary 11-year result of the FIN-RACo study [abstract]. Ann Rheum Dis 2007;66(Suppl II):91.
19. Mäkinen H, Kautiainen H, Hannonen P, et al. Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. J Rheumatol 2007;34:316-21.
20. Sokka T, Mäkinen H, Puolakka K, et al. Remission as the treatment goal - the FIN-RACo trial. Clin Exp Rheumatol 2006;24(6 Suppl 43):S-74-6.
21. Leirisalo-Repo M, Kautiainen H, Laasonen L, et al. A randomized, double-blinded, placebo-controlled study on addition of infliximab to the FIN-RACo DMARD combination therapy for initial six months in patients with early active rheumatoid arthritis. The NEO-RACo study [abstract]. Ann Rheum Dis 2008;67(Suppl II):50.
22. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146:406-15.
23. Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp Rheumatol 2006;24(6 Suppl 43):S-77-82.
24. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
25. van der Kooij SMG, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, et al. Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 2008;67:266-9
26. Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, et al. Clinical and Radiological Outcomes in Recent Onset Rheumatoid Arthritis after 5 Years of DAS-steered Treatment in the BeSt-Study[abstract]. ACR/ARHP Annual Scientific Meeting 2008.
27. Soubrier M, Puéchal X, Sibilia J, et al. Evaluation of two strategies (initial methotrexate monotherapy versus its combination with adalimumab) in management of early active rheumatoid arthritis during the first year of evolution: data from the GUEPARD trial.[abstract]. Ann Rheum Dis 2008;67(Suppl II):331.
28. Saunders SA, Capell HA, Stirling A, et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. Arthritis Rheum 2008;58:1310-17.
29. Ferraccioli GF, Gremese E, Tomietto P, et al. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) 2002;41:892-8.
30. Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. Rheumatology (Oxford) 2008;47:59-64.
31. Brenol CV, Xavier RM, da Cunha V, et al. Daily practice feasibility and effectiveness of tight control of disease activity in the treatment of rheumatoid arthritis: optimizing the use of traditional disease-modifying anti-rheumatic drugs (DMARDS) [abstract] Ann Rheum Dis 2008;67(Suppl II):163.
32. Proudman SM, Keen HI, Stamp LK, et al. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. Semin Arthritis Rheum 2007;37:99-111.
33. Kuper I, Hoekstra M, ten Klooster P, Vermeer M, et al. Remission can be achieved in 50% of early rheumatoid arthritis patients after 25 weeks in daily clinical practice. [abstract]. Ann Rheum Dis 2008;67(Suppl II):48.